Jounce Therapeutics

-$0.12 (-1.33%) As of 3:47 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JNCE and other ETFs, options, and stocks.

About JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.

CEO
Richard Murray
Employees
128
Headquarters
Cambridge, Massachusetts
Founded
2013

JNCE Key Statistics

Market Cap
455.45M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
330.83K
High Today
$9.06
Low Today
$8.78
Open Price
$9.06
Volume
38.83K
52 Week High
$14.84
52 Week Low
$5.03

JNCE Earnings

-$0.82
-$0.26
$0.30
$0.86
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Nov 4, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure